Physician profile
Jonathan N Ginns
NPI 1962737692
$116,958.40
in general payments reported to CMS, 2019-2025
26 companies · $67K in 2025
The $67K reported for 2025 was more than what 99% of Adult Congenital Heart Disease providers received nationally (typical 2025 total: $272).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $67.35 · 2021: $848 · 2022: $4,898 · 2023: $24K · 2024: $20K · 2025: $67K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $83K · Travel and Lodging: $22K · Food and Beverage: $4,774 · Consulting Fee: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $82,559.00 |
| Travel and Lodging | $22,311.87 |
| Food and Beverage | $4,774.03 |
| Consulting Fee | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $112,609.22 | 2022-2025 | Camzyos |
| Abbott Laboratories | $1,955.57 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Amplatzer Amulet |
| Celgene Corporation | $300.00 | 2022 | |
| Pfizer INC. | $276.40 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $271.11 | 2020-2023 | |
| Cvrx, INC. | $243.85 | 2023-2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $215.21 | 2020-2025 | Onpattro |
| Abiomed | $169.72 | 2023-2024 | Impella |
| Medtronic, INC. | $166.04 | 2025 | Corevalve Evolut R |
| Bayer Healthcare Pharmaceuticals INC. | $152.09 | 2025 | |
| Amgen INC. | $84.08 | 2021-2023 | Repatha |
| Novo Nordisk INC | $68.41 | 2024 | Ozempic |
| Edwards Lifesciences Corporation | $64.91 | 2021 | |
| Impulse Dynamics (USA) INC. | $55.30 | 2023 | Optimizer |
| Boston Scientific Corporation | $49.77 | 2022-2025 | Watchman Flx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $46.96 | 2023 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.19 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $29.23 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.15 | 2024 | Jardiance |
| Ge Healthcare | $25.04 | 2023 | |
| Kestra Medical Technology Services, INC. | $21.53 | 2025 | Assure Wcd |
| Atricure, INC. | $21.42 | 2025 | Atriclip Laa Exclusion System |
| Regeneron Healthcare Solutions, INC. | $20.97 | 2022 | |
| Esperion Therapeutics, INC. | $18.81 | 2021 | |
| Chiesi USA, INC. | $14.85 | 2021 | |
| Siemens Medical Solutions USA, INC. | $13.57 | 2023 | Naeotom Alpha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Ginns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.